Highlights Dr. Reddy's Laboratories Limited

Stocks

DRREDDY

INE089A01031

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:48 18/06/2026 pm IST			5-day change	1st Jan Change
1,267.80 ^INR	-0.09%		-0.57%	-0.26%

17/06	US progesterone supplies tighten as menopause treatment demand grows	RE
16/06	Innoviva Specialty Therapeutics, Inc. Enters Distribution And Licensing Agreement With Dr. Reddy?s Laboratories Ltd. For XACDURO In Select International Markets	CI

Highlights

16/06	Innoviva Specialty Therapeutics, Inc. Enters Distribution And Licensing Agreement With Dr. Reddy?s Laboratories Ltd. For XACDURO In Select International Markets	CI
13/06	Dr. Reddy?s Laboratories Announces First-To-Market Launch Of Bosutinib Tablets 400Mg, A Generic Equivalent Of Bosulif, In The United States	CI
19/05	R-Pharm Group of Companies and Dr. Reddy?S Laboratories Ltd. Signs Agreement to Localize Production of Toripalimab for Tumor Therapy	CI
16/05	Dr. Reddy?S Laboratories Ltd. Launches Generic Semaglutide Injection in Canada	CI
13/05	Dr. Reddy's Laboratories' Consolidated Profit Plunges in Fiscal Q4	MT
12/05	Dr. Reddy's Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
12/05	Dr. Reddy's to Launch Generic Ozempic in Canada This Month	MT
12/05	Dr. Reddy's to Launch Generic Ozempic in Canada This Month, Bloomberg Reports	MT
12/05	Dr Reddy's got marketing authorization for generic semaglutide tablets in India from DCGI	RE
12/05	Dr. Reddy's Q4 consol net PAT 2.21 billion rupees; IBES est. 9.25 billion rupees	RE
12/05	Indian drugmaker Dr Reddy's posts quarterly profit slump	RE
12/05	Dr. Reddy's Laboratories Limited announces Annual dividend, payable on August 22, 2026	CI
29/04	Dr. Reddy's Laboratories Receives Health Canada Approval for Generic Semaglutide	MT
29/04	Dr Reddys Laboratories Ltd Receives Health Canada Approval For Generic Semaglutide Injection	CI
29/04	Dr. Reddy's Laboratories Gets Regulatory Nod to Sell Semaglutide Injection in Canada	MT
29/04	Dr. Reddy's Laboratories Gets Regulatory Nod to Sell Semaglutide Injection in Canada	MT
29/04	Dr Reddy's receives Health Canada approval for semaglutide injection	RE
24/04	Dr Reddys Laboratories Ltd Clarifies Status of Semaglutide Injection Approval	CI
16/04	Dr. Reddy's Laboratories Board to Consider Final Dividend for Fiscal 2026	MT
07/04	Enspirit Technology Services Private Limited entered into an agreement to acquire Svaas Wellness Limited from Dr. Reddy's Laboratories Limited for INR 22.3 million.	CI
23/03	Dr Reddys Laboratories Ltd Announces Launch of India's First Dcgi-Approved Semaglutide Injection Obeda for Type 2 Diabetes	CI
06/03	Dr Reddy's says DOJ closes inquiry under Foreign Corrupt Practices Act for Dr. Reddy's Laboratories	RE
24/02	Dr Reddy's says SEC concludes investigation with no enforcement action against co	RE
20/02	Dr. Reddy's Announces USFDA Acceptance to Review its Biologics License Application for Proposed Interchangeable Biosimilar, Abatacept	CI
18/02	Dr. Reddy's Laboratories Limited agreed to acquire Trademarks Progynova®, Cyclo-Progynova® and related assets from Mercury Pharma Group Limited for $32.1 million.	CI